Clinical trials
Prostate Cancer Screening clinical trials
Below are recruiting prostate cancer screening clinical trials, each written for real people, not researchers. We’re tracking 317 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Chandler, ArizonaAges 18 years+ - NCT07082920RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
Sarasota, FloridaAges 18 years+ - NCT06787053Recruiting
MRI imaging for oxygen-starved tumors
This study uses MRI scans to find areas of low oxygen in tumors and see if adjusting radiation treatment can help. It is open to adults with bladder, cervix, or prostate cancer who are getting radiation therapy at the Christie NHS Foundation Trust.
ManchesterAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT07177937RecruitingPhase 1
Study of DXC014 for advanced solid tumors
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+ - NCT06161506RecruitingPhase 2
Electrical stimulation for urinary incontinence after prostate cancer treatment
This trial tests a non-surgical, non-drug treatment that uses gentle electrical stimulation on the skin to help strengthen the muscles that control urine leakage. It's for men who still have urinary incontinence at least 6 months after their prostate cancer treatment.
Bethesda, MarylandAges 18–120 - NCT07316686RecruitingPhase 1
Study of docetaxel and lutetium-PSMA for first-line treatment of metastatic prostate cancer
This trial tests a combination of chemotherapy (docetaxel) and a targeted radiation therapy (lutetium-PSMA) as a first treatment for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to see if this combination is safe and effective.
São PauloAges 18 years+ - NCT07218666RecruitingPhase 2
Zanzalintinib for aggressive prostate cancer
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Milwaukee, WisconsinAges 18 years+ - NCT05646485Recruiting
Bladder cancer screening for people at higher risk
This trial tests screening for bladder cancer in people who have higher risk due to age, smoking, and certain job exposures. It may help find bladder cancer earlier when treatment can be more effective.
Dallas, TexasAges 50 years+ - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06818682RecruitingPhase 2
Shortened hormone therapy with radiation for high-risk prostate cancer
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
Mumbai, MaharashtraAges 19–99 - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06084234RecruitingPhase 4
National liver cancer screening trial
This trial is testing a new way to screen for liver cancer in people with cirrhosis or chronic hepatitis B. It aims to find cancer earlier so it can be treated more effectively.
Los Angeles, CaliforniaAges 18–85 - NCT07164443RecruitingPhase 3
Study of Pasritamig with or without JNJ-87189401 for advanced prostate cancer
This study tests a new combination therapy for advanced prostate cancer that has stopped responding to standard treatments. It aims to see if the combination is more effective than placebo in slowing the cancer's growth.
La Jolla, CaliforniaAges 18 years+ - NCT06826768RecruitingPhase 1
Study of REGN5678 plus cemiplimab for advanced prostate cancer
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
Houston, TexasAges 18 years+ - NCT06600698RecruitingPhase 1/Phase 2
Herbal supplement for rising PSA in prostate cancer
This study tests an herbal supplement called AGN-INM176 in men with prostate cancer whose PSA is rising but whose cancer has not spread. It aims to see if the supplement can safely slow PSA rise without the need for hormone therapy or other treatments.
Hershey, PennsylvaniaAges 40 years+ - NCT05534646RecruitingPhase 2
Carotuximab plus hormone therapy for advanced prostate cancer
This trial tests a new drug called carotuximab given with a standard hormone therapy (apalutamide or enzalutamide) for men with prostate cancer that has stopped responding to current hormone treatments. The goal is to see if this combination can slow the cancer's growth and lower PSA levels.
Duarte, CaliforniaAges 18 years+ - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07755592Recruiting
Using a blood test to find prostate cancer early
This study uses a simple blood test to look for microRNA patterns that may help spot prostate cancer earlier and avoid unnecessary biopsies. If you have elevated PSA or suspicious findings, this test might give more information about your risk.
ShanghaiAges 18 years+ - NCT06276465RecruitingPhase 3
Darolutamide with or without radiation for advanced prostate cancer
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
LorientAges 18 years+ - NCT06193486RecruitingPhase 1
T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Tampa, FloridaAges 18 years+ - NCT06626386Recruiting
Prostate cancer screening with a finger-prick test
This trial is testing a simple finger-prick blood test to measure prostate-specific antigen (PSA) for prostate cancer screening. It aims to make screening easier and more accessible.
Düsseldorf, North Rhine-WestphaliaAges 45–70
Hear when a new Prostate Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer screening?
- Yes. Clin2 currently lists 317 recruiting prostate cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.